Abstract
Objective
The purpose of this study was to assess the effects of alendronate and intranasal salmon calcitonin (sCT) treatments on bone mineral density and bone turnover in postmenopausal osteoporotic women with rheumatoid arthritis (RA) receiving low-dose glucocorticoids.
Methods
Fifty osteoporotic postmenopausal women with RA, who had been treated with low-dose corticosteroids for at least 6 months, were randomized to receive alendronate 10 mg/day or sCT 200 IU/day for a period of 24 months. All patients received calcium supplementation 1,000 mg and vitamin D 400 IU daily. Bone mineral density (BMD) of the lumbar spine, femoral neck, and trochanter was measured annually using dual-energy X-ray absorptiometry. Bone metabolism measurements included urinary deoxypyridinoline (DPD), serum bone alkaline phosphatase (BAP), and serum osteocalcin (OC).
Results
Over 2 years, the lumbar spine (4.34%, P <0.001), femoral neck (2.52%, P <0.05), and trochanteric (1.29%, P <0.05) BMD in the alendronate group increased significantly. The sCT treatment increased lumbar spine BMD (1.75%, P <0.05), whereas a significant bone loss occurred at the femoral neck at month 24 (−3.76%, P <0.01). A nonsignificant decrease in the trochanteric region was observed in the sCT group (−0.81%). The difference between the groups with respect to the femoral neck and trochanteric BMD was statistically significant ( P <0.001and P <0.05, respectively). The decreases in urinary DPD (−21.87%, P <0.001), serum BAP (−10.60%, P <0.01), and OC (−19.59%, P <0.05) values were statistically significant in the alendronate group, whereas nonsignificant decreases were observed in the sCT group (−5.77%, −1.96%, and −4.31%, respectively). A significant difference was found in the DPD and BAP levels between the two treatment groups in favor of the alendronate group at all time points ( P =0.001 and P <0.05, respectively).
Conclusion
The results of this study demonstrated that alendronate treatment produced significantly greater increases in the femoral neck BMD and greater decreases in bone turnover than intranasal sCT in RA patients receiving low dose glucocorticoids.
Similar content being viewed by others
References
Van Jaarsveld CHM, Jacobs JWG, Van Der Veen MJ, Blaauw AAM, Kruize AA, Hofman DM, Brus HLM (2000) Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis 59:468–477
DequekerJ, Maenaut K, Verwilghen J, Westhowens R (1995) Osteoporosis in rheumatoid arthritis. Clin Exp Rheumatol 12:S1–6
Suzuki Y, Mizushima Y (1997) Osteoporosis in rheumatoid arthritis. Osteoporos Int 7 [Suppl 3]:S217–222
Celiker R, Gokce-Kutsal Y, Cindas A, Ariyurek M, Renda N, Koray Z, Basgoze O (1995) Osteoporosis in rheumatoid arthritis: effect of disease activity. Clin Rheumatol 14:429–433
Laan RFJM, van Riel PLCM, van de Putte LBA (1992) Bone mass in patients with rheumatoid arthritis. Ann Rheum Dis 51:826–832
Haugeberg G, Uhlig T, Flach JA, Halse JI, Kvien TK (2000) Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis. Results from 394 patients in the Oslo country rheumatoid arthritis register. Arthritis Rheum 43:522–530
Kroger H, Honkanen R, Saarikoski S, Alhave E (1994) Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis—a population based study. Ann Rheum Dis 53:18–23
Iwamoto J, Takeda T, Ichimura S (2002) Forearm bone mineral density in postmenopausal women with rheumatoid arthritis. Calcif Tissue Int 70:1–8.
Cortet B, Guyot MH, Solau E, Pigny P, Dumoulin F, Flipo RM (2000) Factors influencing bone loss in rheumatoid arthritis: a longitudinal study. Clin Exp Rheumatol 18:683–690
Eastgate JA, Wood NC, Di Giovine FS, Symons JA, Grinlinton FM, Duff GW (1988) Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet 340:706–709
Deodhar AA, Woolf AD (1996) Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol 35:309–322
Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM (1995) Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 22:1055–1059
Saario R, Sonninen P, Mottonen T, Viikari J, Toivanen A (1999) Bone mineral density of the lumbar spine in patients with advanced rheumatoid arthritis: influence of functional capacity and corticosteroid use. Scand J Rheumatol 28:363–367
Saag K, Koehnke R, Cadwell J, Brasington R, Burmeister LD, Zimmerman B, et al (1994) Low dose long-term corticosteroid therapy in RA: an analyis of serious adverse events. Am J Med 96:115–123
LoCasvio V, Bonucci E, Imbimbo B, Ballanti P, Adami S, Milani S, et al (1990) Bone loss in response to long-term glucocorticoid therapy. Bone Miner 8:39–51
Peel NF, Moore DJ, Barrington NA, Bax DE, Eastell R (1995) Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 54:801–806
Cooper C, Coupland C, Mitchell M (1995) Rheumatoid arthritis, corticosteroid therapy, and hip fractures Ann Rheum Dis 54:49–52
Hasegawa J, Nagashima M, Yamamoto M, Nishijima T, Katsumata S, Yoshino S (2003) Bone resorption and inflammatory inhibition of intermittent cyclical etidronate therapy in rheumatoid arthritis. J Rheumatol 30:474–479
Jenkins EA, Walker-Bone KA, Wood A, McCrae FC, Cooper C, Calwey MID (1999) The prevention of corticosteroid-induced bone loss with intermittent cyclical editronate. Scand J Rheumatol 28:152–156
>Geusens P, Dequeker J, Vanhoof J, Stalmans R, Boonen S, Joly J, et al (1998) Cyclical editronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised, placebo controlled study. Ann Rheum Dis 57:724–727
Eastell R, Devogelaer JP, Peel NFA, Chines AA, Bax DE, et al (2000) Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 11:331–337
Eggelmeijer F, Papapoulos SE, vanPaessen H, Dijkmans BEC, Valkema R, Westedt ML (1996) Increased bone mass with pamidronate treatment in rheumatoid arthritis. Arthrits Rheum 39:396–402
Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299
Yilmaz L, Ozoran K, Gunduz OH, Ucan H, Yucel M (2001) Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids. Rheumatol Int 20:65–69
Sileghem A, Geusens P, Dequeker J (1992) Intranasal calcitonin for the prevention of bone erosion and bone loss in rheumatoid arthritis. Ann Rheum Dis 51:761–764
Adachi JD, Bensen WG, Bell MJ, Bianchi FA, Cividino AA, Craig GL, et al (1997) Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol 36:255–259
Arnett FC, Edworthy SM, Bloch DA, et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324
Prevoo MLL, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM (1995) Modified disease activity scores that include 28-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48
Kirwan JR, Reeback JS (1986) Stanford health assessment questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 25:206–209
Sambrook PN, Kotowicz M, Nash P, Styles CB, Naganathan V, Henderson-Briffa KN (2003) Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 18:919–924
Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucucorticoids. Arthritis Rheum 44:202–211
Healey JH, Paget SA, Williams-Russo P, Szatrowski TP, Schneider R, Spiera H (1996) A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 58:73–80
Sambrook P, Birmingham J, Kelly P, Kempler S, Nuguyen T, Pocock N, et al (1993) Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 17:1747–1752
Kotaniemi A, Piirainen H, Paimela L, Leirisalo-Repo M, Uoti-Reilama K, Lahdentausta P, et al (1996) Is continuous intranasal salmon calitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy? J Rheumatol 23:1875–1879
Cranney A, Welch V, Adachi JD, Homik J, Shea B, Suarez-Almazor ME, et al (2000) Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2:CD001983
Takahashi M, Kushida H, Hoshino H, Ohishi T, Inoue T (1997) Evaluation of bone turnover in postmenopausal, vertebral fracture, and hip fracture using biochemical markers for bone formation and resorption. J Endocrinol Invest 20:112–117
Seriolo B, Ferretti V, Sulli A, Caratto E, Fasciolo D, Cutolo M (2002) Serum osteocalcin levels in premenopausal rheumatoid arthritis patients. Ann N Y Acad Sci 966:502–507
Hall GM, Spector TD, Delmas PD (1995) Markers of bone metabolism in postmenopausal women with rheumatoid arthritis: effects of corticosteroids and hormone replacement therapy. Arthritis Rheum 38:902–906
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tascioglu, F., Colak, O., Armagan, O. et al. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin. Rheumatol Int 26, 21–29 (2005). https://doi.org/10.1007/s00296-004-0496-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-004-0496-3